vaxigrip suspenzija za injiciranje v napolnjeni injekcijski brizgi
sanofi pasteur - ha seva b/brisbane/60/2008, divji tip, podoben sevu b/brisbane/60/2008; ha seva nymc x-275 (iz seva a/michigan/45/2015, podoben sevu a/michigan/45/2015; ha seva nymc x-263b (iz seva a/hong kong/4801/2014), podoben sevu a/hong kong/48 - suspenzija za injiciranje v napolnjeni injekcijski brizgi - ha seva b/brisbane/60/2008, divji tip, podoben sevu b/brisbane/60/2008 15 µg / 0,5 ml ha seva nymc x-275 (iz seva a/michigan/45/2015, podoben sevu a/michigan/45/201515 µg / 0,5 ml ha seva nymc x-263b (iz seva a/hong kong/4801/2014), podoben sevu a/hong kong/4815 µg / 0,5 ml; ha seva nymc x-275 (iz seva a/michigan/45/2015, podoben sevu a/michigan/45/2015 15 µg / 0,5 ml ha seva nymc x-263b (iz seva a/hong kong/4801/2014), podoben sevu a/hong kong/4815 µg / 0,5 ml; ha seva nymc x-263b (iz seva a/hong kong/4801/2014), podoben sevu a/hong kong/48 15 µg / 0,5 ml - cepivo proti gripi, z delci virusov ali s površinskimi antigeni, inaktivirano
idflu
sanofi pasteur s.a. - virus influence (inaktivirano, split) od naslednjih vrst:a/california/7/2009 (h1n1)pdm09 - kot seva a/california/7/2009, nymc x-179a)/hong kong/4801/2014 (h3n2) - kot sev (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - kot sev b/brisbane/60/2008, divji tip) - influenza, human; immunization - cepiva - preprečevanje gripe pri posameznikih, starih 60 let in več, zlasti pri tistih, ki imajo povečano tveganje za povezane zaplete. uporaba idflu mora temeljiti na uradnih priporočilih.
intanza
sanofi pasteur europe - virus influence (inaktivirano, split) od naslednjih vrst:a/california/7/2009 (h1n1)pdm09 - kot seva a/california/7/2009, nymc x-179a)/hong kong/4801/2014 (h3n2) - kot sev (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - kot sev b/brisbane/60/2008, divji tip) - influenza, human; immunization - cepiva - preprečevanje gripe pri posameznikih, starih 60 let in več, zlasti pri tistih, ki imajo povečano tveganje za povezane zaplete. uporaba intanza mora temeljiti na uradnih priporočilih.
advantix za pse od 40 do 60 kg
bayer animal health gmbh 51368 leverkusen nemčija 8 -
minirin melt 60 mikrogramov peroralni liofilizat
ferring gmbh - dezmopresin - peroralni liofilizat - dezmopresin 60 µg / 1 liofilizat - dezmopresin
gestoden/etinilestradiol gedeon richter 60 mikrogramov/15 mikrogramov
etinilestradiol; gestoden - filmsko obložena tableta - etinilestradiol 15 µg / 1 tableta gestoden60 µg / 1 tableta; gestoden 60 µg / 1 tableta - gestoden in etinilestradiol
gestoden/etinilestradiol gedeon richter 60 mikrogramov/15 mikrogramov
etinilestradiol; gestoden - filmsko obložena tableta - etinilestradiol 15 µg / 1 tableta gestoden60 µg / 1 tableta; gestoden 60 µg / 1 tableta - gestoden in etinilestradiol
gestoden/etinilestradiol gedeon richter 60 mikrogramov/15 mikrogramov
etinilestradiol; gestoden - filmsko obložena tableta - etinilestradiol 15 µg / 1 tableta gestoden60 µg / 1 tableta; gestoden 60 µg / 1 tableta - gestoden in etinilestradiol
virbagen omega
virbac s.a. - rekombinantni omega interferon mačjega izvora - immunostimulants, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. pri mačkah, okuženih s fiv, je bila smrtnost nizka (5%) in na zdravljenje ni vplivala.
arexvy
glaxosmithkline biologicals s.a. - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - infekcije respiratornih sincicijskih virusov - cepiva - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.